Live Breaking News & Updates on Valeria Fantin

Stay updated with breaking news from Valeria fantin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

19.12.2023 - Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET . Seite 1 ....

Valeria Fantin , Global Head Of Oncology Research At Sanofi , Global Head , Oncology Research , Engager Therapeutics , Innate Pharma Aktie , Nnate Pharma Spons Ads Aktie ,

Innate Pharma SA: Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by ....

Valeria Fantin , Gewinn Nur , Arthur Rouill , Henry Wheeler , Mondher Mahjoubi , Exchange Commission , Global Head Of Oncology Research At Sanofi , French Financial Markets Authority , Oncology Development At Sanofi , Company Annual Report On Form , Innate Pharma , Euronext Paris , Chief Executive Officer , Global Head , Oncology Research , Oncology Development , Myelodysplastic Syndromes , Presentation Time , Engager Therapeutics , Private Securities Litigation Reform Act , Risk Factors , Universal Registration Document , Annual Report ,

Innate Pharma (IPHA) Reports Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia

Innate Pharma (IPHA) Reports Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Arthur Rouill , Henry Wheeler , Valeria Fantin , Eric Vivier , Bristol Myers Squibb , Novo Nordisk , Company Annual Report On Form , French Financial Markets Authority , Exchange Commission , Global Head Of Oncology Research At Sanofi , Wall Street , Nature Biotechnology , Chief Scientific Officer , Innate Pharma , Global Head , Oncology Research , Engager Therapeutics , Natural Killer , Euronext Paris , Private Securities Litigation Reform Act , Risk Factors , Universal Registration Document , Annual Report ,

Sanofi and Innate Pharma expand cancer therapeutics collaboration

Sanofi and Innate Pharma expand cancer therapeutics collaboration
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Valeria Fantin , Innate Pharma , Cell Engager Therapeutics , Yannis Morel ,

Sanofi to license Innate Pharma's NK cell platform

Sanofi will license Innate Pharma’s B7H3 ANKET platform, which is creating a new class of molecules to induce synthetic cancer immunity. ....

Valeria Fantin , Global Head Of Oncology Research At Sanofi , Innate Pharma , Natural Killer Cell , Engager Therapeutics , Global Head , Oncology Research , Executive Vice President , Innate Pharmaceutical ,